FDA Approves Livtencity As First Drug To Treat Post-transplant Cytomegalovirus

The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...

from RTT - Top Story https://ift.tt/3cJuC4N
via IFTTT